

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

LY2784544

产品编号: D50754

CAS: 1229236-86-5

分子式: C23H25ClFN7O

纯度: ≥98%

InChi: InChI=1S/C23H25CIFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)2

0(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)

)

InChi Key: SQSZANZGUXWJEA-UHFFFAOYSA-N

Smiles: CC1C=C(NN=1)NC1C=C(CN2CCOCC2)C2=NC(C)=C(CC3C=CC(Cl)=CC=3F)N2N=1

外观: 固体粉末

作用通路: FGFR

溶解性: DMSO up to 100 mM

保存条件: Store in dry, dark place for one year.

产品介绍: LY2784544 is highly potent and selective mutant JAK2 (V617F) inhibitor with an IC50 of ~55

nM. It also inhibits IL-3-activated wild type JAK2 with an IC50 of 2.26 μ M. Similarly in the proliferation assay, LY2784544 shows anti-proliferative activity in JAK2 V617F-driven cells with an IC50 of 68 nM, compared to 1.36 μ M in wild type JAK2-driven cells and 0.94 μ M in JAK3-driven cells. LY2784544 significantly inhibits STAT5 phosphorylation in JAK2-V617F Ba/F3 xenografts. Currently LY2784544 is being investigated in a clinical trial for the treatment of essential thrombocythemia, polycythemia vera, and primary myelofibrosis.